It is one day after the House Energy and Commerce Committee sent a declination letter to the four Congressmen that had been requesting a further review of the questionable FDA ruling for Dendreon’s (DNDN) Provenge, the company’s groundbreaking Prostate cancer drug. Now, a news release shows another beneficial study result...
Tag: cancer drug
- DHUnplugged #443: The Glass is Fully FullFeb 13, 2019
- DHUnplugged #442: BTD Or STR ?Feb 06, 2019
- DHUnplugged #441: Yearning for EarningsJan 30, 2019
- DHUnplugged #440: Cloudy with a Chance of CorrectionJan 23, 2019
- DHUnplugged #439: Black Eyed FinanceJan 16, 2019